文献速递精神分裂症与精神病性障碍会诊联络精神医学

氯氮平使用与精神分裂症患者感染风险:香港人群队列研究

Clozapine use and risk of infections in patients with schizophrenia in Hong Kong: a population-based cohort study.
PubMed 文献 · Lancet Psychiatry · 2025-07-28

结果显示氯氮平组总体感染发生率高于奥氮平组(加权HR 1·25,95%CI 1·13-1·39),风险随年龄增长而升高,上、下呼吸道感染和胃肠道感染是主要贡献。

要点

  • 氯氮平组总体感染加权发生率为7·26/100人年,高于奥氮平组的6·00/100人年。
  • 加权HR为1·25(95%CI 1·13-1·39),加权绝对发生率差为1·27/100人年(95%CI 0·55-2·04)。
  • 年龄越大风险越高:18-44岁HR 1·24、45-54岁HR 1·41、55岁及以上HR 1·45。

核心结论

  • 与奥氮平相比,氯氮平使用与精神分裂症患者总体感染发生率升高相关,且风险随年龄增长而增大,临床应在氯氮平治疗获益与感染防控之间权衡。

研究设计与样本

  • 这是一项基于香港医院管理局全港电子健康记录的人群队列研究,纳入2002年1月1日至2023年12月31日记录中18岁及以上、ICD-9-CM编码295诊断精神分裂症的个体。
  • 纳入持续使用氯氮平或奥氮平至少90天者,并排除此前使用少于两种其他抗精神病药者,以识别长期抗精神病药使用且存在治疗抵抗的患者;奥氮平因化学结构相似、适应症常重叠而被选为对照。
  • 主要结局为任何感染性疾病(按一系列ICD-9-CM编码识别),亚型作为次要结局;采用倾向评分逆概率治疗加权平衡协变量,以Cox比例风险模型估计加权HR,并估计加权绝对发生率差。

主要发现

  • 奥氮平组平均年龄为45·33岁(SD 14·55),高于氯氮平组的40·59岁(SD 12·26);无族裔数据。
  • 氯氮平组总体感染加权发生率为7·26/100人年,奥氮平组为6·00/100人年,加权HR 1·25(95%CI 1·13-1·39),加权绝对发生率差为1·27/100人年(95%CI 0·55-2·04)。
  • 按年龄分层,18-44岁加权HR 1·24(95%CI 1·08-1·42),加权绝对差0·81/100人年(95%CI 0·13-1·55);45-54岁加权HR 1·41(95%CI 1·15-1·72),加权绝对差2·23/100人年(95%CI 0·82-3·86);55岁及以上加权HR 1·45(95%CI 1·14-1·84),加权绝对差4·70/100人年(95%CI 1·29-8·45)。
  • 次要分析显示,上呼吸道感染、下呼吸道感染和胃肠道感染是氯氮平较奥氮平感染发生率升高的主要贡献因素。

关键数值与推荐

  • 与奥氮平相比,氯氮平使用者的总体感染加权HR为1·25(95%CI 1·13-1·39),加权绝对发生率差为1·27/100人年(95%CI 0·55-2·04)。
  • 年龄分层加权HR:18-44岁1·24(95%CI 1·08-1·42)、45-54岁1·41(95%CI 1·15-1·72)、55岁及以上1·45(95%CI 1·14-1·84)。

临床怎么用

  • 临床医生应在权衡氯氮平治疗获益的同时采取感染控制措施,包括定期监测和预防策略。

局限性

  • 原文未报告该研究的局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infection is the leading natural cause of mortality in patients with schizophrenia, and use of antipsychotics might be associated with an increased risk of infections. This study aimed to examine the association of clozapine use with the incidence of various infectious diseases. METHODS: In this population-based cohort study, we used territory-wide electronic health records from the Hong Kong Hospital Authority. Individuals aged 18 years or older with a diagnosis of schizophrenia (ICD-9-CM code 295) based on records from Jan 1, 2002, to Dec 31, 2023 were considered for inclusion. We included patients who used clozapine or olanzapine continuously for at least 90 days and excluded those who had previously used fewer than two other antipsychotic medications, to identify a cohort of patients with long-term antipsychotic use who had treatment resistance. Olanzapine was chosen as a comparator due to its similar chemical structure and often overlapping indication with clozapine. The primary outcome was the occurrence of any infectious disease, identified by a range of ICD-9-CM codes, with subtypes analysed as secondary outcomes. Propensity score-based inverse probability of treatment weighting was applied to balance covariates. Weighted hazard ratios (HRs) for infection in patients using clozapine versus those using olanzapine were estimated by Cox proportional hazards models. Weighted absolute differences in incidence rate were also estimated. People with lived experience of schizophrenia were not involved in the design or conduct of the study. FINDINGS: We identified 53 092 individuals with clozapine or olanzapine initiation between Jan 1, 2004 and Dec 31, 2023, with 2002-03 used as a wash-out period to exclude individuals having used the two antipsychotics before. After exclusion of participants without a schizophrenia diagnosis and who did not meet the other selection criteria, the final cohort consisted of 11 051 patients (1450 using clozapine and 9601 using olanzapine). Overall, 6031 (54·6%) patients were female and 5020 (45·4%) were male. Mean age was higher in the olanzapine group (45·33 years [SD 14·55]) than in the clozapine group (40·59 years [12·26]). No ethnicity data were available. The incidence of infection overall was increased in patients using clozapine (weighted incidence rate 7·26 per 100 person-years) compared with those using olanzapine (6·00 per 100 person-years; weighted HR 1·25 [95% CI 1·13-1·39]). The weighted absolute difference in incidence rate was 1·27 infections per 100 person-years (95% CI 0·55-2·04). The risk was notably higher in older age ranges, with weighted HRs rising from 1·24 (1·08-1·42) in those aged 18-44 years (weighted absolute difference 0·81 per 100 person-years [0·13-1·55]) to 1·41 (1·15-1·72) in those aged 45-54 years (2·23 per 100 person-years [0·82-3·86]), and 1·45 (1·14-1·84) in those aged 55 years or older (4·70 per 100 person-years [1·29-8·45]). Secondary analyses identified upper and lower respiratory tract infections and gastrointestinal infections as primary contributors to the observed increased incidence associated with clozapine versus olanzapine use. INTERPRETATION: Clinicians should balance the therapeutic benefits of clozapine with infection control measures, including regular monitoring and preventive strategies. FUNDING: InnoHK initiative of the Innovation and Technology Commission of Hong Kong. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hu Y, Tian W, Wei C, et al. Clozapine use and risk of infections in patients with schizophrenia in Hong Kong: a population-based cohort study. Lancet Psychiatry. 2025. PMID: 40744048. doi:10.1016/S2215-0366(25)00201-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。